Sweekruti Hegde, Ayesha Mahajan, Kruthikaa, Vinayak M, KG Kallur, Prasanth, BS Ajaikumar, Radheysham Naik and G Lohith*
Department of Radiation Oncology, Healthcare Global Hospital, Bangalore, India
*Corresponding Author: G Lohith, Department of Radiation Oncology, Healthcare Global Hospital, Bangalore, India.
Received: August 19, 2020; Published: October 20, 2020
We hereby report a case of a 44 year old female with invasive ductal carcinoma of left breast with metastasis to subcarinal and supraclavicular lymph nodes, right lung and left adrenal gland. She was diagnosed with fibroblast activated PET-CT and biopsy. Her PET-CT was done prior to chemotherapy and post chemotherapy and is further discussed in the report. She was operated (BCS) and received eribulin after a TCH regimen which showed regression of tumor in the fibroblast activated PET-CT. We further discuss how the fibroblasts in the cancer stroma is involved in the radionuclide based diagnosis of cancer. The presence of fibroblasts only in the tumor tissue that defines its accuracy in the cancer diagnosis. Eribulin is a microtubule inhibitor and reverses the epithelial mesenchymal transformation and hence is a effective drug in the treatment of different types of cancer. Eribulin has an effect on the cancer associated fibroblast that helps to use fibroblast activated PET CT as a method to measure the efficacy of Eribulin treatment in the breast cancer.
Keywords: Fibroblast; PET-CT Scan; Eribulin; HER2 NEU; Metastatic Breast Cancer
Citation: G Lohith., et al. “Role of Fibroblast Activated PET-CT Scan to Evaluate Response to Eribulin in HER2 NEU Positive Metastatic Breast Cancer- A Case Report". Acta Scientific Cancer Biology 4.11 (2020): 17-19.
Copyright: © 2020 G Lohith., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.